Showing results (391-400 of 434) with videos related to
Sort By:
Pageof 44
Journal of Medicinal Chemistry|July 16, 2015
Synthesis and in Vivo Evaluation of [123I]Melanin-Targeted AgentsMaxine P Roberts, Vu Nguyen, Mark E Ashford, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 6, 2025
Texture analysis of [18F]FDG PET/CT may stratify risk in stage II colorectal cancer - discovery findingsLouise Rice, Balaji Ganeshan, Simon Wan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaMalik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.Blood|April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissionsSasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.Cancer Discovery|June 30, 2022
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II StudyPeter Savas, Louisa L Lo, Stephen J Luen, et al.Annals of Neurology|January 5, 2019
Metabolic patterns and seizure outcomes following anterior temporal lobectomyVarduhi Cahill, Benjamin Sinclair, Charles B Malpas, et al.European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitorsKaren E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.Endocrine-Related Cancer|July 20, 2026
Whole genome and exome sequencing of pancreatic NET to investigate PRRT responseEmma Boehm, Aidan Flynn, Alex Caneborg, et al.The Journal of Clinical Investigation|January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceKathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.Journal of Neuroendocrinology|December 14, 2023
Use and perceived utility of [18 F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.Pageof 44